Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
2014
164
LTM Revenue n/a
LTM EBITDA -$265M
$680M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cogent Biosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of -$265M.
In the most recent fiscal year, Cogent Biosciences achieved revenue of n/a and an EBITDA of -$205M.
Cogent Biosciences expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Cogent Biosciences valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | -$142M | -$205M | -$264M | -$265M | XXX |
EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | -Infinity% | XXX |
Net Profit | -$72.3M | -$140M | -$192M | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 14, 2025, Cogent Biosciences's stock price is $8.
Cogent Biosciences has current market cap of $887M, and EV of $680M.
See Cogent Biosciences trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$680M | $887M | XXX | XXX | XXX | XXX | $-2.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 14, 2025, Cogent Biosciences has market cap of $887M and EV of $680M.
Cogent Biosciences's trades at n/a LTM EV/Revenue multiple, and -2.6x LTM EBITDA.
Analysts estimate Cogent Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cogent Biosciences and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $680M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | -2.6x | XXX | XXX | XXX |
P/E | -3.5x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -4.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCogent Biosciences's NTM/LTM revenue growth is Infinity%
Cogent Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Cogent Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cogent Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cogent Biosciences and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 29% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cogent Biosciences acquired XXX companies to date.
Last acquisition by Cogent Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Cogent Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Cogent Biosciences founded? | Cogent Biosciences was founded in 2014. |
Where is Cogent Biosciences headquartered? | Cogent Biosciences is headquartered in United States of America. |
How many employees does Cogent Biosciences have? | As of today, Cogent Biosciences has 164 employees. |
Who is the CEO of Cogent Biosciences? | Cogent Biosciences's CEO is Mr. Andrews R. Robbins, M.B.A.. |
Is Cogent Biosciences publicy listed? | Yes, Cogent Biosciences is a public company listed on NAS. |
What is the stock symbol of Cogent Biosciences? | Cogent Biosciences trades under COGT ticker. |
When did Cogent Biosciences go public? | Cogent Biosciences went public in 2018. |
Who are competitors of Cogent Biosciences? | Similar companies to Cogent Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Cogent Biosciences? | Cogent Biosciences's current market cap is $887M |
What is the current EBITDA of Cogent Biosciences? | Cogent Biosciences's last 12-month EBITDA is -$265M. |
What is the current EV/EBITDA multiple of Cogent Biosciences? | Current EBITDA multiple of Cogent Biosciences is -2.6x. |
Is Cogent Biosciences profitable? | Yes, Cogent Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.